ReviewWiley interdisciplinary reviews. Nanomedicine and nanobiotechnology2021
Opportunities and challenges for the clinical translation of structured DNA assemblies as gene therapeutic delivery and vaccine vectors.
Review in Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 42 citations in OpenAlex.
- Prospects of DNA nanotechnology in stroke repair and regeneration.Communications biology · 2026Review
- DNA Origami-Cyanine Nanocomplex for Precision Imaging of KRAS-Mutant Pancreatic Cancer Cells.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Plugging synthetic DNA nanoparticles into the central dogma of life.Chemical communications (Cambridge, England) · 2024Review
- Charge Detection Mass Spectrometry Enables Molecular Characterization of Nucleic Acid Nanoparticles.ACS nano · 2024Article
- Folding molecular origami from ribosomal RNA.Journal of nanobiotechnology · 2024Article
- Review
- In vitro transcription of self-assembling DNA nanoparticles.Scientific reports · 2023Article
- Methods and Limitations of Augmenting Mesenchymal Stem Cells for Therapeutic Applications.Advances in wound care · 2023Review
- Enhancing antibody responses by multivalent antigen display on thymus-independent DNA origami scaffolds.bioRxiv : the preprint server for biology · 2023Article
- Evaluation of Nonmodified Wireframe DNA Origami for Acute Toxicity and Biodistribution in Mice.ACS applied bio materials · 2023Article
- Evaluation of non-modified wireframe DNA origami for acute toxicity and biodistribution in mice.bioRxiv : the preprint server for biology · 2023Article
- Functionalizing DNA origami to investigate and interact with biological systems.Nature reviews. Materials · 2023Article
- Targeted cell delivery of mesenchymal stem cell therapy for cardiovascular disease applications: a review of preclinical advancements.Frontiers in cardiovascular medicine · 2023Review
- Approaches towards biomaterial-mediated gene editing for cancer immunotherapy.Biomaterials science · 2022Review
- Artificial Immune Cell, AI-cell, a New Tool to Predict Interferon Production by Peripheral Blood Monocytes in Response to Nucleic Acid Nanoparticles.Small (Weinheim an der Bergstrasse, Germany) · 2022Article
- Article
- Epigenetic therapy targeting bone marrow mesenchymal stem cells for age-related bone diseases.Stem cell research & therapy · 2022Review
- Antisense technology as a potential strategy for the treatment of coronaviruses infection: With focus on COVID-19.IET nanobiotechnology · 2022Review
- Rapid DNA origami nanostructure detection and classification using the YOLOv5 deep convolutional neural network.Scientific reports · 2022Article
- Critical review of nucleic acid nanotechnology to identify gaps and inform a strategy for accelerated clinical translation.Advanced drug delivery reviews · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Gene therapeutics including siRNAs, anti-sense oligos, messenger RNAs, and CRISPR ribonucleoprotein complexes offer unmet potential to treat over 7,000 known genetic diseases, as well as cancer, through targeted in vivo modulation of aberrant gene expression and immune cell activation. Compared with viral vectors, nonviral delivery vectors offer controlled immunogenicity and low manufacturing cost, yet suffer from limitations in toxicity, targeting, and transduction efficiency. Structured DNA assemblies fabricated using the principle of scaffolded DNA origami offer a new nonviral delivery vector with intrinsic, yet controllable immunostimulatory properties and virus-like spatial presentation of ligands and immunogens for cell-specific targeting, activation, and control over intracellular trafficking, in addition to low manufacturing cost. However, the relative utilities and limitations of these vectors must clearly be demonstrated in preclinical studies for their clinical potential to be realized. Here, we review the major capabilities, opportunities, and challenges we foresee in translating these next-generation delivery and vaccine vectors to the clinic. This article is categorized under: Therapeutic Approaches and Drug Discovery > Emerging Technologies Biology-Inspired Nanomaterials > Nucleic Acid-Based Structures Therapeutic Approaches and Drug Discovery > Nanomedicine for Oncologic Disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.